SCHEMBL2276256

SCHEMBL2276256

O=C(Nc1cc(CCc2ccccc2)ccc1C(=O)O)c1ccc(-n2cccc2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.45
SIRT1 Q96EB6 1/20 0.45
SIRT3 Q9NTG7 1/20 0.45
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA4 P22748 2/20 0.43
CA7 P43166 2/20 0.43
PLK1 P53350 6/20 0.43
PLK3 Q9H4B4 4/20 0.43
STING1 Q86WV6 1/20 0.43
HDAC1 Q13547 4/20 0.41
LTC4S Q16873 1/20 0.40
MCL1 Q07820 1/20 0.40
BCL2A1 Q16548 1/20 0.40
SERPINE1 P05121 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14428225 0.92 SIRT2 (0.44) SIRT2SIRT1SIRT3STING1HDAC1
SCHEMBL2270642 0.87 HDAC1 (0.43) SIRT2SIRT1SIRT3HDAC1NPC1
SCHEMBL2268313 0.85 KDM5A (0.47) CA12CA1CA4CA7PLK1
SCHEMBL2274078 0.85 SMN1; SMN2 (0.49) HDAC1NPC1ALDH1A1LMNAMAPT
SCHEMBL2269782 0.84 ACLY (0.56) STING1HDAC1SERPINE1NPC1RAB9A
SCHEMBL2270290 0.83 AOC3 (0.48) HDAC1NPC1ALDH1A1LMNAMAPT
SCHEMBL2270356 0.81 SERPINE1 (0.48) SIRT2SIRT1SIRT3MCL1SERPINE1
SCHEMBL2270812 0.81 ALDH1A1 (0.47) CA12CA1CA4CA7PLK1
SCHEMBL2275929 0.79 KMT2A (0.62) CA12CA1CA4CA7PLK1
SCHEMBL2271421 0.77 DHODH (0.63) PLK1PLK3HDAC1LTC4SMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SIRT2 1147/4885SIRT1 675/4885SIRT3 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.